View Post

HPV Treatment Demonstrates Positive Phase 2 Efficacy When Treating Precancerous Vulvar Dysplasia

In COVID-19, Latest News by Precision Vaccinations

A Pennsylvania based biotechnology company announced positive efficacy results for an open-label Phase 2 trial of VGX-3100 to treat HPV-16 and HPV-18-associated vulvar dysplasia. 
A 25 percent or more reduction in HPV-16/18-associated vulvar HSIL (high-grade squamous intraepithelial lesion) was observed for 63 percent of trial participants (12 of 19) treated with VGX-3100 at six months post-treatment, stated INOVIO Pharmacuticals, Inc.’s press release issued on January 6, 2021.

View Post

WHO Grants Prequalification of Sabin-IPV Polio Vaccine

In COVID-19, Latest News by Precision Vaccinations

South Korean-based biotechnology company announced that its Sabin-Inactivated Polio Vaccine (Sabin-IPV) Eupolio™ is the first to receive the World Health Organization (WHO) prequalification be supplied globally.
LG Chem stated in a press release, ‘Eupolio demonstrated excellent phase III results in 2019, inducing high antibody titers against both wild-type and Sabin polioviruses, which will also protect against circulating vaccine-derived polioviruses (cVDPV) that make up the majority of polio cases in recent years.’